Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
13 juin 2024 08h00 HE
|
Umoja Biopharma, Inc.
Umoja Biopharma Announces Publication in Blood Highlighting Successful Generation of In Vivo CAR T-cells in Non-Human Primate Modeling
Umoja Biopharma to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
19 mars 2024 08h30 HE
|
Umoja Biopharma, Inc.
SEATTLE, March 19, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma Announces Appointment of Britton Russell as Chief Financial Officer
28 févr. 2024 08h30 HE
|
Umoja Biopharma, Inc.
SEATTLE,, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma to Participate in a Fireside Chat at the Evercore ISI 2024 Emerging Biotech Conference
22 févr. 2024 08h30 HE
|
Umoja Biopharma, Inc.
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of...
Umoja Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
02 janv. 2024 08h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T...
Umoja Biopharma Presents Preclinical Data at the 65th American Society of Hematology Annual Meeting Demonstrating In Vivo CAR T Cell Generation with Potent and Highly Durable Activity
11 déc. 2023 13h30 HE
|
Umoja Biopharma, Inc.
Durable B cell aplasia up to 76 days observed in non-human primates following a single dose of VivoVec™ particles without lymphodepletion, exceeding industry benchmarks for ex vivo CAR T cell...
Umoja Biopharma Announces Oral Presentation at the 65th American Society of Hematology Annual Meeting
02 nov. 2023 09h43 HE
|
Umoja Biopharma, Inc.
SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced that...
Umoja Biopharma Announces Opening of Development and Manufacturing Facility in Louisville, Colorado
19 oct. 2023 10h00 HE
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, announced today the...
Umoja Biopharma to Present at the 2023 Cell & Gene Meeting on the Mesa
05 oct. 2023 14h30 HE
|
Umoja Biopharma, Inc.
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc., a transformative immuno-oncology company creating off-the-shelf treatments for solid and hematologic cancers, today announced that...
Umoja Biopharma’s VivoVec Platform Presents Encouraging Proof-of-Concept Data in Ongoing Non-Human Primate Study at the 8th CAR-TCR Summit
01 sept. 2023 12h30 HE
|
Umoja Biopharma, Inc.
Preliminary data from ongoing preclinical study include rapid, durable chimeric antigen receptor (CAR) T cell generation in vivo after a single infusion of VivoVec particles Additional data to be...